Night Vision Disturbances - Market Insight, Epidemiology And Market Forecast - 2032
Key Highlights:
- The Night Vision Disturbance (NVD) market is projected to witness consistent growth throughout the forecast period (2023-2032). The market size of Night Vision Disturbance in the 7MM is expected to increase, driven by better diagnosis and launch of emerging therapies.
- DelveInsight's analyst projects that among the total cases of NVD in 7MM approximately 44% of cases were from the US. As per our estimations, in 2022, the US accounted for nearly 24 million diagnosed prevalent cases of NVD.
- In the 7MM, the market mainly consisted of supportive care, which generated nearly around USD 3,200 million in 2022.
- The total market size of the Night Vision Disturbance treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatment, namely, NYXOL.
DelveInsight's "Night Vision Disturbance (NVD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the NVD, historical and forecasted epidemiology and the Night Vision Disturbance (NVD) market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Night Vision Disturbance (NVD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Night Vision Disturbance (NVD) market size from 2019 to 2032. The report also covers current Night Vision Disturbance treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2019-2032
Disease Understanding and Treatment Algorithm
Night Vision Disturbance (NVD) Overview
Night Vision Disturbance (NVD) refers to the impairment or disruption of one's ability to see clearly in low-light or nighttime conditions, often experienced by individuals using night vision technology or devices. It can result from various factors, such as bright light sources, glare, and insufficient contrast, leading to reduced visibility and potential safety hazards. NVD mitigation strategies may include adjusting device settings, employing anti-glare measures, or developing advanced technology to enhance nighttime vision without causing discomfort or visual impairment.
Night Vision Disturbance (NVD) Diagnosis
The process of diagnosing night vision disturbance typically entails an ocular examination to eliminate any underlying ocular conditions, such as cataracts or retinal issues. Additionally, specialized assessments, such as contrast sensitivity testing, may be conducted to evaluate the precise nature and extent of the impairment. The recommended course of action for early symptoms is observation because the patient's cerebral processing and adaptability are at work. The subjective questionnaire, which involves asking patients about their symptoms and rating them on a scale, is the assessment technique used the most frequently for night vision impairments.
Further details related to country-based variations are provided in the report
Night Vision Disturbance (NVD) Treatment
The treatment of NVD depends on the etiology; NVD brought on by hereditary factors are incurable, and its care is based on managing symptoms, improving quality of life, and lessening the burden of the condition. To minimize NVD, several approaches are performed, including conservative techniques and surgical re-treatments. Conservative techniques include using contact lenses to create artificial pupils or using off-label treatments, mostly miotics and adrenergic agonists, to contract the pupils.
Night Vision Disturbance (NVD) Epidemiology
As the market is derived using the patient-based model, the Night Vision Disturbance epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Night Vision Disturbance (NVD), in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032. As per DelveInsight's estimations, the total diagnosed prevalent cases of Night Vision Disturbance in the 7MM was approximately 55 million cases in 2022 and are projected to increase during the forecast period.
- The estimated overall count of individuals diagnosed with NVD in the United States was approximately 24 million in 2022, and is expected to increase at a substantial CAGR throughout the study period (2019-2023).
- Among the 7MM, EU4 and the UK accounted for nearly 22 million diagnosed prevalent cases of NVD, and these cases are expected to increase during the forcast period (2023-2032).
- Among EU4 and the UK, Germany had the highest diagnosed prevalent population of NVD, with about 6 million cases, followed by France and Italy in 2022. On the other hand, Spain had the least diagnosed prevalent population among EU4 and the UK countries in 2022.
- In Japan, there were around 8.6 million diagnosed prevalent cases of NVD in 2022. These cases are expected to decrease at a significant CAGR due to a decline in the population.
Night Vision Disturbance (NVD) Drug Chapters
The drug chapter segment of the Night Vision Disturbance report encloses a detailed analysis of Night Vision Disturbance marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Night Vision Disturbance clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
Nyxol: Ocuphire Pharma/Viatris
Nyxol is a novel ophthalmic treatment for multiple front-of-the-eye disorders, including NVD, presbyopia, and medically-induced mydriasis. It is a proprietary ophthalmic formulation of phentolamine mesylate, an alpha-1 and alpha-2 inhibitor that has been approved previously as an injectable for other indications, allowing a more efficient development pathway for approval. Nyxol has demonstrated a differentiated product profile by moderately reducing pupil size (which leads to improved night and day vision), significantly lowering intraocular pressure, and convenient once-daily dosing. Currently, the company has completed Phase III trial of Nyxol for the treatment of NVD and plans to start another Phase III trial.
Note: Detailed emerging therapies assessment will be provided in the final report of NVD.
Night Vision Disturbance (NVD) Market Outlook
Currently, there is no definitive cure for NVD. Ophthalmologists typically conduct an assessment of NVD by examining the patient's eyes and testing their vision. Early symptoms are best managed through observation, as the patient's neural processing and adaptation mechanisms come into play.
NVD treatment aims to mitigate symptoms and risk factors through diet modifications, pharmacological interventions, and invasive procedures as needed. Off-label usage of miotics, such as pilocarpine, carbachol, and aceclidine, and adrenergic agonists, such as brimonidine tartrate to reduce night vision symptoms in ophthalmology is significant.
Supportive care options (miotics and adrenergic agonists) are major revenue generators in the current treatment landscape.
- The total market size of Night Vision Disturbance (NVD) in the 7MM reached approximately USD 3,200 million in 2022. Projections indicate a substantial growth during the forecast period.
- Out of the 7MM, the United States dominated the market in 2022, representing the largest share at 54%.
- In 2022, EU4 and the UK captured an estimated USD 1,025 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2022, followed by France, Italy, and the UK. Spain accounted for the least market size in the same year.
- Japan alone represented approximately 14% of the total NVD market in 2022, projected to decrease at a significant CAGR during the study period (2019-2032).
- The market for Night Vision Disturbance is expected to experience positive growth with the approval of potential drugs like NYXOL.
Night Vision Disturbance (NVD) Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, NYXOL in the US is expected to be launched by 2025, with medium uptake.
Further detailed analysis of emerging therapies drug uptake in the report…
Night Vision Disturbance (NVD) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Night Vision Disturbance emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Night Vision Disturbance evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility. These KOLs were from reputed organizations, such as, Keck School of Medicine of the University of Southern California, Los Angeles; Department of Ophthalmology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Nouvelle Clinique de l'Union, Saint Jean, France; Section of Ophthalmology, University of Palermo, Italy; Department of Ophthalmology, Tajimi Municipal Hospital, Tajimi, Japan; and others.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Night Vision Disturbance market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report:
- The report covers a segment of key events, an executive summary, descriptive overview of Night Vision Disturbance (NVD), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
- Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
- A detailed review of the Night Vision Disturbance (NVD) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help shape and drive the 7MM Night Vision Disturbance (NVD) market.
Night Vision Disturbance (NVD) Report Insights
- Patient Population
- Therapeutic Approaches
- Night Vision Disturbance Pipeline Analysis
- Night Vision Disturbance Market Size and Trends
- Existing and Future Market Opportunity
Night Vision Disturbance (NVD) Report Key Strengths
- 10 years Forecast
- The 7MM Coverage
- Night Vision Disturbance Epidemiology Segmentation
- Key Cross Competition
- Conjoint Analysis
- Drugs Uptake and Key Market Forecast Assumptions
Night Vision Disturbance (NVD) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
Key Questions
Market Insights
- What was the Night Vision Disturbance (NVD) total market size, the market size by therapies, and market share (%) distribution in 2019, and how would it all look in 2032? What are the contributing factors for this growth?
- What unmet needs are associated with the current treatment market of Night Vision Disturbance (NVD)?
- How will NYXOL compete with the existing therapies for Night Vision Disturbance (NVD) during the study period?
- Which drug is going to be the largest contributor in 2032?
- What are the pricing variations among different geographies for approved and off-label therapies?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
- What are the disease risk, burdens, and unmet needs of Night Vision Disturbance (NVD)? What will be the growth opportunities across the 7MM concerning the patient population of Night Vision Disturbance (NVD)?
- What is the historical and forecasted Night Vision Disturbance (NVD) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
- Why do only limited patients appear for diagnosis?
- Which country is more prevalent for Night Vision Disturbance (NVD) and why?
- What factors are affecting the diagnosis of the indication?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for treating Night Vision Disturbance (NVD)? What are the current guidelines for treating Night Vision Disturbance (NVD) in the US and Europe?
- How many companies are developing therapies for treating Night Vision Disturbance (NVD)?
- How many emerging therapies are in the mid-stage and late stage of development for treating Night Vision Disturbance (NVD)?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the key designations that have been granted for the emerging therapies for Night Vision Disturbance (NVD)?
- Patient acceptability in terms of preferred treatment options as per real-world scenarios?
- What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
- What are the 7MM historical and forecasted markets of Night Vision Disturbance (NVD)?
Reasons to Buy:
- The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Night Vision Disturbance (NVD) Market.
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
- Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.
Frequently Asked Questions
1. What is the forecast period covered in the report?
- The Night Vision Disturbance (NVD) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2032, providing a projection of market dynamics and trends during this timeframe.
2. Who are the key players in NVD market?
- NVD market is very scare. The major players are Ocuphire Pharma/Viatris which are currently developing drug for the treatment of NVD, rest market is now contributed with off-label therapies.
3. How is the market size estimated in the forecast report?
- The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.
4. What is the key driver of NVD market?
- The increase in diagnosed prevalent cases of NVD attributed with current population size.
5. What is the expected impact of emerging therapies or advancements in NVD treatment on the market?
- Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the NVD treatment market. Market forecast reports provide analysis and predictions regarding the potential impact of these developments.
6. Does the report provide insights into the competitive landscape of the market?
- The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Night Vision Disturbance (NVD) market.
Table of Contents
1. Key Insights
2. Report Introduction
3. Night Vision Disturbance (NVD) Market Share Distribution
- 3.1. Market Share (%) Distribution of NVD in 2019
- 3.2. Market Share (%) Distribution of NVD in 2032
4. Methodology of NVD Epidemiology and Market
5. Executive Summary of Night Vision Disturbance (NVD)
6. Key Events
7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Types of NVD
- 7.3. Causes and Risk Factors
- 7.4. Symptoms
- 7.5. Diagnosis
- 7.6. Treatment
8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumption and Rationale
- 8.3. Total Diagnosed Prevalent Cases of NVD in the 7MM
- 8.4. The United States
- 8.4.1. Total Diagnosed Prevalent Cases of NVD in the US
- 8.5. EU4 and the UK
- 8.5.1. Germany
- 8.5.1.1. Total Diagnosed Prevalent Cases of NVD in Germany
- 8.5.2. France
- 8.5.2.1. Total Diagnosed Prevalent Cases of NVD in France
- 8.5.3. Italy
- 8.5.3.1. Total Diagnosed Prevalent Cases of NVD in Italy
- 8.5.4. Spain
- 8.5.4.1. Total Diagnosed Prevalent Cases of NVD in Spain
- 8.5.5. The United Kingdom
- 8.5.5.1. Total Diagnosed Prevalent Cases of NVD in the UK
- 8.6. Japan
- 8.6.1. Total Diagnosed Prevalent Cases of NVD in Japan
9. Patient Journey
10. Emerging Drug
- 10.1. Key Cross
- 10.2. NYXOL: Ocuphire Pharma/Viatris, Inc.
- 10.2.1. Product Description
- 10.2.2. Other Developmental Activities
- 10.2.3. Clinical Development
- 10.2.4. Clinical Trials Information
- 10.2.5. Safety and Efficacy
- 10.2.6. Product Profile
- 10.2.7. Analysts' Views
11. NVD: Market Analysis
- 11.1. Key Findings
- 11.2. Key Market Forecast Assumptions
- 11.3. Market Outlook
- 11.4. Total Market Size of NVD in the 7MM
- 11.5. Market Size of NVD by Therapies in the 7MM
- 11.6. The United States
- 11.6.1. Total Market Size of NVD
- 11.6.2. Market Size of NVD by Therapies
- 11.7. EU4 and the UK
- 11.7.1. Germany
- 11.7.1.1. Total Market Size of NVD
- 11.7.1.2. Market Size of NVD by Therapies
- 11.7.2. France
- 11.7.2.1. Total Market Size of NVD
- 11.7.2.2. Market Size of NVD by Therapies
- 11.7.3. Italy
- 11.7.3.1. Total Market Size of NVD
- 11.7.3.2. Market Size of NVD by Therapies
- 11.7.4. Spain
- 11.7.4.1. Total Market Size of NVD
- 11.7.4.2. Market Size of NVD by Therapies
- 11.7.5. The United Kingdom
- 11.7.5.1. Total Market Size of NVD
- 11.7.5.2. Market Size of NVD by Therapies
- 11.8. Japan
- 11.8.1. Total Market Size of NVD
- 11.8.2. Market Size of NVD by Therapies
12. Key Opinion Leaders' Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
- 15.1. The United States
- 15.1.1. Centre for Medicare and Medicaid Services (CMS)
- 15.2. In EU4 and the UK
- 15.2.1. Germany
- 15.2.2. France
- 15.2.3. Italy
- 15.2.4. Spain
- 15.2.5. The United Kingdom
- 15.3. Japan
16. Appendix
- 16.1. Bibliography
- 16.2. Acronyms and Abbreviations
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
